Zobrazeno 1 - 10
of 9 523
pro vyhledávání: ''
Autor:
Sanjay Prakash, Anurag Prakash
Publikováno v:
BMJ Case Rep
In addition to the legs, restless legs syndrome (RLS) affects various other parts of the body, including the arms, abdomen, face, head-neck, oral cavity, genital area and bladder. RLS is also associated with several comorbid conditions, including irr
Autor:
Julia Nazco-Casariego, Laura Ramos, Fernando Gutiérrez-Nicolás, Raquel De La Barreda, Enrique Quintero, Inmaculada Alonso-Abreu, Javier Ramos-Rodríguez, Marta Carrillo-Palau
Publikováno v:
Gastroenterología y Hepatología (English Edition). 45:335-341
Nonadherence to medication is common in patients with inflammatory bowel disease (IBD) and can result in disease complications, therapy escalation, and the need for corticosteroids. The aim of this study was to assess the adherence to self-administer
Autor:
Markus Cornberg, Christoph Höner zu Siederdissen, George N. Dalekos, Fabien Zoulim, Milan J. Sonneveld, Wai-Kay Seto, Nicole S. Erler, Heiner Wedemeyer, Thomas Berg, Ivana Carey, Jun Yong Park, Kosh Agarwal, Yasuhito Tanaka, Sang Hoon Ahn, Benjamin Maasoumy, Apichat Kaewdech, Teerha Piratvisuth, Maria Buti, Man-Fung Yuen, George V. Papatheodoridis, Andre Boonstra, Margarita Papatheodoridi, Florian van Bömmel
Publikováno v:
Clinical Gastroenterology and Hepatology, 20(4), e784-e793. W.B. Saunders
Background & Aims: Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg
Autor:
Anil Arora, Nishant Verma, Prateek Shivshankar Padole, Praveen Sharma, Prakash Chand, Ashok Kumar
Publikováno v:
J Clin Exp Hepatol
BACKGROUND: Saroglitazar is a novel, dual peroxisome proliferator-activated receptors-α/γ agonist and is being investigated for the treatment of nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: Consecutive overweight (body mass index
Autor:
Dana J. Lukin, Paul J. Christos, Robert Battat, Waseem Ahmed, Jonathan S. Galati, Ellen Scherl, Anand Kumar, Randy S. Longman
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e361-e379
Background and Aims We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD)
Autor:
Hugh Wright, Angus Lane
Publikováno v:
BMJ Case Rep
Echinococcosis or human hydatid disease is a helminthic infection is caused by Echinococcus species. Classically, cystic echinococcosis is caused by Echinococcus granulosus sensu stricto, E. equinus, E. ortleppi and E. canadensis, though several othe
Publikováno v:
BMJ Case Rep
A 59-year-old man with refractory Cronkhite-Canada syndrome (CCS) had poor clinical response to high-dose intravenous steroids, azathioprine, total parenteral nutrition and best supportive care. He remained highly symptomatic with abdominal pain, dia
Autor:
Thomas Aparicio, Noémie Trystram, Pauline Laly, Barouyr Baroudjian, Philippe Bertheau, Jean-Marc Gornet
Publikováno v:
Annals of Palliative Medicine. 11:837-842
We provide a unique case of haemorrhagic shock complicating a corticosteroid-resistant diffuse ulcerative enteritis in a patient treated with a combination of an anti CTLA-4 and an anti PD-1 for metastatic melanoma. Immunotherapy has changed the pers
Autor:
Nilay Shah, Lindsey R. Sangaralingham, Parambir S. Dulai, Herbert C. Heien, William J. Sandborn, Jeph Herrin, Siddharth Singh
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 2
Clin Gastroenterol Hepatol
Clin Gastroenterol Hepatol
Background and Aims We conducted a retrospective cohort study comparing the risk of serious infections between patients treated with tumor necrosis factor-a (TNFa) antagonists vs. vedolizumab in patients with inflammatory bowel diseases (IBD). Method
Autor:
Vineet Ahuja, Kirandeep Kaur, Saurabh Kedia, Varun Mehta, Pabitra Sahu, Namita Bansal, Sandeep Kaushal, Ramit Mahajan, Arshdeep Singh, Khushdeep Dharni, Ajit Sood, Dharmatma Singh, Vandana Midha
Publikováno v:
Intestinal Research, Vol 20, Iss 1, Pp 64-71 (2022)
Background/Aims: Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects.